Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In Multiple Myeloma

Author: Benzinga Newsdesk | April 29, 2024 09:39am

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:

10 years of market exclusivity once authorized in the EU
Access to the EU centralized authorization procedure
- Reduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees

Posted In: IMMX